Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner safety under the microscope: 2,000 heart patients enrolled

NCT ID NCT04347200

Knowledge-focused Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry is following 2,000 people with chronic coronary artery disease who are taking long-term blood thinners (antiplatelet or anticoagulant drugs). The goal is to track how often serious bleeding or clotting events (like heart attacks or strokes) occur. By understanding these risks, doctors may be able to tailor treatment more safely for each patient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Antiplatelet or anticoagulant drugs (blood thinners)
What this could lead to
If successful, this could help doctors better balance the risks of bleeding and clotting when prescribing long-term blood thinners for heart disease patients.
What could go wrong
This is an observational registry, not a treatment trial, so it won't test a new drug or cure. Results may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2015

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hospitalized or outpatients with confirmed chronic coronary syndromes

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. * Acute coronary syndrome within 12 months before inclusion * Severe chronic heart failure (NYHA IV) * Stroke within 6 months before inclusion * Severe liver or muscle disease * Severe kidney disease / renal failure with creatinine \> 3 mg/dl * Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease (CAD) (E.G., angina, myocardial infarction, and atherosclerotic heart disease (ASHD)) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Angina Pectoris coronary artery disorder myocardial infarction peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease (CAD) (E.G., angina, myocardial infarction, and atherosclerotic heart disease (ASHD)) Peripheral artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

    RECRUITING

    Moscow, 121552, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.